Special Issue "Liver Fibrosis Resolution: From Molecular Mechanisms to Therapeutic Opportunities"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 10543
Interests: nutraceuticals; (poly)phenols; natural products and drug-delivery; signal transduction pathway; molecular pharmacology; wound healing; fibrosis
Special Issues, Collections and Topics in MDPI journals
Liver fibrosis is the main response to chronic liver disease, characterized by an excess deposition of the extracellular matrix (ECM). During fibrogenesis, hepatic stellate cells (HSCs) are activated, followed by cytokine and chemokine release, which induces their trans-differentiation into myofibroblast-like cells. This step is marked by the increased expression of smooth muscle α-actin (α-SMA) and therefore leads to MMP/TIMP imbalance, finally resulting in enhanced production and accumulation of ECM components. Transforming growth factor-β1 (TGF-β1) produced by Kupffer cells, endothelial cells, and hepatocytes has been recognized as a key activator of HSCs in the pathogenesis of liver fibrosis and acts by activating the Smad signaling pathway.
However, liver fibrosis is not a unidirectional progressive process, ultimately leading to liver cirrhosis and organ failure, and could be reversible. The molecular and cellular mechanisms of liver fibrosis regression are modulated by stopping chronic damage, shifting the balance from inflammation to resolution, deactivating myofibroblasts, and finally by ECM degradation.
In recent years, significant progress has been made in the understanding of the contribution of fibrosis in the progression of liver chronic diseases, as well as the development of new antifibrotic therapeutic compounds. Therefore, the purpose of this Special Issue of the International Journal of Molecular Sciences is to collect original research articles and reviews on the cellular and molecular pathways of liver fibrosis resolution, as well as the current status and molecular pharmacology of the new therapeutic compounds (from natural to synthetic compounds) that target liver fibrosis.
Prof. Dr. Anca Hermenean
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cellular signaling pathways
- antifibrotic compounds
- natural compounds
- small molecule inhibitors
- drug delivery systems